Back to Top Skip to main content Skip to sub-navigation

DOD participates in new COVID-19 antibody combination prevention trial

Image of Woman gets blood drawn. Miranda Heilweil gets her blood drawn at Madigan Army Medical Center, Washington, one of five DOD sites where the STORM CHASER trial is studying the efficacy of an antibody product that could prevent COVID-19 in people who have been exposed to the virus within eight days. (U.S. Army photo by Janell Cain)

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts | MHS Toolkits and Branding Guidance

While the Military Health System continues to support the development and distribution of COVID-19 vaccines to counter the ongoing public health threat of the disease, it’s investing in other efforts to counter the SARS-CoV-2 virus.

One of those includes evolving therapeutics as part of the U.S. government’s COVID-19 response through clinical trials of a long-acting antibody combination medicine to prevent COVID-19 among people who have been exposed to the disease.

The intramuscular long-acting antibody product, called AZD7442 and developed by AstraZeneca, is undergoing a phase III clinical trial at five Department of Defense sites to study its efficacy among eligible MHS beneficiaries who have recently been exposed to others with SARS-CoV-2 infection.

“This study will run for one year, although interim and primary analyses will likely occur much earlier in 2021,” said Dr. Simon Pollett, associate scientific director and COVID-19 research area director at the Uniformed Services University of the Health Science’s (USU) Infectious Diseases Clinical Research Program (IDCRP).

Under the name STORM CHASER, Pollett’s program is coordinating teams of physicians, nurses, pharmacists, and clinical research staff at Tripler Army Medical Center in Hawaii, Madigan Army Medical Center in Washington, William Beaumont Army Medical Center in Texas, Naval Medical Center Portsmouth in Virginia, and USU in Maryland. The lead investigators at these sites are Army Col. Viseth Ngauy, Army Col. Anjali Kunz, Dr. Gina Kubicz, Navy Lt. Cmdr. Tida Lee, and Army Lt. Col. Jeffrey Livezey, respectively.

This study is designed to prevent the development of illness in people who have been exposed to COVID-19 in care homes and sites with enhanced risk of disease transmission, under the sponsorship of AstraZeneca with support from the U.S. health information technology and clinical research firm IQVIA. IDCRP is supported through a cooperative agreement with The Henry M. Jackson Foundation for the Advancement of Military Medicine.

Primarily, STORM CHASER seeks to determine if the antibody injection can prevent COVID-19 in people who were exposed to the SARS-CoV-2 virus – which causes the disease – within the last eight days, but have not yet developed symptoms, explained Pollett. “This may include those exposed by household contacts, in crowded working conditions, in health care settings, and other scenarios,” he added.

A secondary objective of the study is examining whether the antibody injection can reduce viral shedding in those who may develop the disease after receiving the injection, said Pollett. Viral shedding occurs when the virus replicates inside the body and is released to the environment, making the host person contagious to others.

“Reduced viral shedding may perhaps correlate with reduced transmissibility, but this requires further study,” said Pollett.

STORM CHASER also aims to see if individuals who receive the AZD7442 injection after SARS-CoV-2 exposure experience less severe symptoms of COVID-19. Likewise, the clinical trial seeks to explore “sequencing of breakthrough virus to look at antibody escape mutations,” said Navy Capt. Timothy Burgess, IDRCP director. This will help determine whether AZD7442 protects across a range of SARS-CoV-2 strains, including newly emerged variants.

AZD7442 contains infection-fighting proteins called monoclonal antibodies that work to neutralize the virus, thus preventing COVID-19. Each dose is given once as two intramuscular shots in each gluteal region, within eight days of exposure.

If clinical trials are successful and the product receives emergency use authorization from the Food and Drug Administration, this investigational product would become another tool to defeat the COVID-19 pandemic. Two vaccines, by Pfizer-BioNTech and Moderna, are available to the U.S. population older than 16 and 18 years of age, respectively, under FDA’s EUA, with three more vaccines, including AstraZeneca’s, currently in clinical trials.

The vaccines work inside the body by triggering the immune system to make antibodies that will block or kill the SARS-CoV-2 spike protein if it enters the body, which results in immunity to coronavirus. They are given to healthy individuals who have not been exposed to the virus to protect them against getting seriously ill from the disease if they become infected or exposed, and studies are still being conducted to gauge their ability to keep people from spreading the virus.

AZD7442 may provide very rapid protection against COVID-19 in individuals who have been exposed because it is given while the virus is incubating, said Burgess. But those who have already received the COVID-19 vaccine are not eligible to participate in the study.

“The investigational product is intended to provide rapid immunity after exposure, with up to six months of protection thereafter,” said Burgess. “STORM CHASER is examining the efficacy of this.”

If the study is successful in achieving its objective of preventing COVID-19 after exposure, the hope, according to Pollett, is that transmission chains will also be stopped by preventing such COVID-19 cases, but further study is required.

This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority in partnership with the Department of Defense; Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense; under Contract No. W911QY-21-9-0001.

If interested in participating in the STORM CHASER trial - please contact Julia Rozman at: julia.rozman.ctr@usuhs.edu.

You also may be interested in...

Defense Department Announces Distribution of COVID-19 Tests for Military Beneficiaries

Article
2/25/2022
A Soldier assigned to the Connecticut National Guard helps load a shipment of at-home COVID-19 testing kits into a truck at a regional distribution point in North Haven, Connecticut, Jan. 3, 2022. These kits were picked up by representatives from local towns and municipalities to be handed out to their communities.

The Department of Defense will offer at-home COVID-19 tests for military beneficiaries at military hospitals or clinics, on a supply available basis, in the coming weeks.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | At-Home COVID-19 Tests | Coronavirus

Latasha Smith: Warrior against COVID-19

Article Around MHS
2/18/2022
Military personnel looking at a patient's cardiac rhythm

Air Force Tech. Sgt. Latasha Smith, an Airman assigned to the 86th Operational Medical Readiness Squadron, was celebrated as Airlifter of the Week, Jan. 27, 2022, after leading the assault against COVID-19 for over a year.

Recommended Content:

Coronavirus

Military Medical Units Support Civilian Hospitals Strained By COVID-19 Surge

Article
2/14/2022
Air Force Staff Sgt. Bradley Gorman, a medical technician assigned to a military medical team deployed to Yuma, Arizona performs a nasal swab at the Yuma Regional Medical Center’s COVID testing drive-thru in Yuma, Jan. 17, 2022.

Thousands of service members have been supporting civilian hospitals with testing, vaccinations and treatment of seriously ill patients.

Recommended Content:

Coronavirus

COVID-19 therapeutics support DOD pandemic response

Article Around MHS
2/11/2022
Military personnel getting COVID-29 doses ready

The U.S. Army Medical Materiel Agency is helping to protect the operational force by distributing several new therapeutic options that help to lessen the symptoms of mild-to-moderate cases of COVID-19 and keep Soldiers, their families and beneficiaries out of the hospital.

Recommended Content:

Coronavirus

COVID-19 Health Action Response for Marines continues to study long-term effects of COVID-19 on Marines

Article Around MHS
2/10/2022
Medical military personnel talking to a patient

A team composed of U.S. Navy medical personnel and civilian technicians based out of the Naval Medical Research Center in Silver Spring, Maryland, assembled during the initial outbreak of COVID-19 to study the short and long-term effects that the virus has on Marines. 

Recommended Content:

Coronavirus

Does CSM Gragg Have COVID-19?

Video
2/9/2022
Does CSM Gragg Have COVID-19?

CSM Gragg demonstrates how to use a COVID-19 at home rapid test.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | At-Home COVID-19 Tests | Coronavirus

Getting up-to-date on your COVID-19 vaccine

Article Around MHS
2/8/2022
Military personnel giving the COVID-19 vaccine

The U.S. Guard Coast is that we have vaccines to help prevent serious illness if you contract COVID-19.

Recommended Content:

Coronavirus

DOD COVID-19 Practice Management Guide Version 8

Technical Document
1/31/2022

This Practice Management Guide does not supersede DOD Policy. It is based upon the best information available at the time of publication. It is designed to provide information and assist decision making. It is not intended to define a standard of care and should not be construed as one. Neither should it be interpreted as prescribing an exclusive course of management. It was developed by experts in this field. Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional making use of this guideline is responsible for evaluating the appropriateness of applying it in the setting of any particular clinical situation. The Practice Management Guide is not intended to represent TRICARE policy. Further, inclusion of recommendations for specific testing and/or therapeutic interventions within this guide does not guarantee coverage of civilian sector care. Additional information on current TRICARE benefits may be found at www.tricare.mil or by contacting your regional TRICARE Managed Care Support Contractor.

Recommended Content:

Coronavirus | COVID-19 Information for Military Treatment Facility Directors

Oregon National Guard surging to support hospitals again

Article Around MHS
1/27/2022
Oregon Army National Guard touring a hospital

Hundreds of Oregon National Guard members are increasing support of hospitals throughout the state in their second hospital relief mission during the COVID-19 pandemic.

Recommended Content:

Coronavirus | Readiness Capabilities

Public Health nurses offer insights on living with COVID-19 now, looking into future

Article Around MHS
1/25/2022
The Challenges of Living with COVID

One of the more challenging jobs for any public health professional is dealing with unpredictability inherent in outbreaks like the current COVID-19 pandemic.

Recommended Content:

Coronavirus

Do You Have COVID-19? Influenza? Or is it RSV? Here’s What to Look For

Article
1/24/2022
Military personnel preparing a COVID-19 test sample for processing

Knowing the symptoms of COVID-19/RSV/Flu will help your medical treatment

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Seasonal Influenza Vaccine | Coronavirus

Medical Leaders Address COVID-19 Concerns During Family Forum

Article
1/21/2022
Navy Petty Officer 3rd Class Jemuel Macabali, from San Diego, Calif., gives the COVID-19 vaccine to staff at Camp Lemonnier, in Djibouti, Aug. 13, 2021.

Top health leaders talk about the recent spike in COVID-19 infections and the impact on the military community.

Recommended Content:

Coronavirus

Navy Hospital Corpsman steps into the breach in the war on COVID-19

Article Around MHS
1/18/2022
Hospitalman Hector Conde standing in front of a immunization office's refrigeration

First responders and those fighting on the medical battleground have earned well-deserved recognition for their efforts.

Recommended Content:

Coronavirus

Critically ill COVID Patient Delivers Baby While on Heart-Lung Bypass

Article
1/11/2022
Retired U.S. Marine Corps Gunnery Sgt. Carlos Hernandez and his wife, Ashley, take a family portrait with their six children. Ashley is BAMC’s first patient to give birth while on Extracorporeal Membrane Oxygenation.

Hernandez, a Marine Corps spouse and mother of five, is BAMC’s first patient to give birth while on Extracorporeal Membrane Oxygenation.

Recommended Content:

Women's Health | Coronavirus

DHA Form 236: Pediatric (5-11 years) COVID-19 Vaccine Screening and Immunization Documentation, v8

Form/Template
1/7/2022

This form is used to determine if the COVID-19 vaccine can be administered to the pediatric patient. (Version 8, June 2022)

Recommended Content:

Coronavirus and the COVID-19 Vaccine | COVID-19 Vaccine Efforts | Children's Health | Immunization Healthcare
<< < 1 2 3 4 5  ... > >> 
Showing results 16 - 30 Page 2 of 28
Refine your search
Last Updated: August 30, 2021

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.